<DOC>
	<DOCNO>NCT01263457</DOCNO>
	<brief_summary>This National , Multicentre , Observational Registry study Adherence Long Term Outcomes Therapy paediatric subject use Easypod™ electromechanical device growth hormone treatment hospital UK ass level adherence subject receive SAIZEN® via Easypod™ .</brief_summary>
	<brief_title>To Assess Level Adherence Subjects Receiving SAIZEN® Via Easypod™ UK</brief_title>
	<detailed_description>Subjects enrol multicenter longitudinal observational registry . Parents/subjects provide Informed Consent/assent upload data populationbased analysis optionally adhere patient adherence support program design improve adherence , ultimately , clinical outcome . Adherence data primarily derive Easypod™ device combine physician data entry outcome measure . Data collect retrospectively prospectively . This allow establishment adherence profile explore hypothesis patient adherence support program improve adherence subsequent clinical outcome . Collected data also analyze multinational pooled analysis comparable national study . Primary Objective : - To assess level adherence subject receive SAIZEN via easypod™ Secondary Objectives : - To describe impact adherence clinical outcome subject receive SAIZEN via easypod™ - To identify adherence subject profile - To assess impact adherence Insulin-like Growth Factor 1 ( IGF-1 ) ( i.e . , within normal range ) - To assess endocrinological profile include Triiodothyronine ( T3 ) , Thyroxine ( T4 ) , Thyroid-stimulating hormone ( TSH ) , Insulin-like Growth Factor 1 ( IGF-1 ) Insulin-like Growth Factor-Binding Protein 3 ( IGFBP-3 ) level - Temporal profile IGF-1 IGFBP-3 level</detailed_description>
	<mesh_term>Growth Disorders</mesh_term>
	<criteria>Administered growth hormone via easypod electromechanical injection device accord Summary Product Characteristics ( SmPC ) Over age 2 year Under 18 year age , 18 without fusion growth plat ( confirmed Investigator , relevant ) Appropriate Informed Consent/Assent provide Patients take growth hormone growth plate fuse ( i.e . take growth hormone 's metabolic effect ) Contraindications Saizen define SmPC condition precludes use SAIZEN give patient Use investigational drug participation interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Growth disorder</keyword>
	<keyword>Saizen</keyword>
	<keyword>EasypodTM</keyword>
	<keyword>Growth hormone</keyword>
	<keyword>Pediatric subject</keyword>
</DOC>